C.A. Yedema

Use of Serum Tumor Markers in the Differential Diagnosis between Ovarian and Colorectal Adenocarcinomas

C.A. Yedema, Peter Kenemans, Th. Wobbes et al. · Tumor Biology · 1992 · 72 citations

CA 125 half-life in ovarian cancer: a multivariate survival analysis

C.A. Yedema, Peter Kenemans, Feja J. Voorhorst et al. · British Journal of Cancer · 1993 · 55 citations · Full text

Medicine, Gynecology, Cancer Treatment +5

Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays

C.A. Yedema, Leon F.A.G. Massuger, Jo Hilgers et al. · International Journal of Cancer · 1988 · 39 citations

CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery

C.A. Yedema, Peter Kenemans, Chris M.G. Thomas et al. · European Journal of Cancer · 1993 · 35 citations

Surgical Oncology, Ca 125, Medicine +6

Monoclonal antibodies that discriminate between human ovarian carcinomas and benign ovarian tumours

Otto C. Boerman, W.K. Makkink, C.M.G. Thomas et al. · European Journal of Cancer and Clinical Oncology · 1990 · 11 citations

Human Ovarian Carcinomas, Medicine, Benign Ovarian Tumours +7